BL-M14D1 is named as an intervention in 3 current clinical trials in our China and USA registers. 3 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Sichuan Baili Pharmaceutical Co., Ltd (2). The most-studied condition is Small Cell Lung Cancer Metastatic or Locally Advanced.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
NCT07654400 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer
|
Phase 2 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | China |
|
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
NCT06505824 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer, Neuroendocrine Tumors
|
Phase 1 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | China |
|
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
NCT07080242 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer
|
Phase 1 | Recruiting | SystImmune Inc. | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Sichuan Baili Pharmaceutical Co., Ltd. | 2 |
| SystImmune Inc. | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
| Clinical trials in USA | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China and USA registers name BL-M14D1 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 3 trials are recruiting: 2 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Sichuan Baili Pharmaceutical Co., Ltd (2) and SystImmune Inc (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how BL-M14D1 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how BL-M14D1 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists BL-M14D1 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.